Jefferies Global Healthcare Conference. Namal Nawana CEO and President. June 1, 2015 New York. Namal Nawana, CEO and President Alere Inc.

Transcription

1 Jefferies Global Healthcare Conference June 1, 2015 New York Namal Nawana CEO and President Namal Nawana, CEO and President 2015 Alere Inc.

2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. This includes all statements concerning or relating to our ability to improve clinical outcomes, improve access to care and to reduce healthcare costs. Such forwardlooking statements are estimates reflecting management s best judgment based upon current information and involve a number of risks and uncertainties. Actual results and the timing of certain events could differ materially from those projected or contemplated by the forwardlooking statements due to numerous factors, including without limitation, the risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2014, as well as in our Quarterly Reports on Form 10-Q. Our Company undertakes no obligation to update forward-looking statements.

3 Global Leader in Rapid Diagnostics #1 global provider of rapid, point of care tests 1 1B tests delivered in 2014 #1 in global toxicology testing and specialty labs 2 $1.4B in revenue from outpatient settings #1 global provider of POC infectious disease testing 3 1st CLIA-waived molecular POC test 4 1 Frost & Sullivan, Global Point-of-Care Testing (POCT) Market, April 2013, p Alere Company Estimates. 3 BCC Research, Espicom, Cowen, Calorama, Company Estimates. 4 FDA press release,

4 2014 Revenue Profile BROAD & DIVERSE CUSTOMER BASE STRONG RECURRING REVENUE GLOBAL PRESENCE Consumables 76% Infectious Disease 28% Cardio - metabolic 33% North America 54% Consumer Other 14% Toxicology 25% Services 20% Africa, Latin America 12% Asia Pacific 13% Europe 21% Instruments 3% Royalties 1% Markets Products Geographies 3

5 Leading Market Position Business Market Size $M Market Position, # 4-yr expected CAGR, % Market Cardiac markers Blood gas 880 Emerging 12 Cardiometabolic HbA1c Lipids Anti Coag Product Anti Coag Service Mail Order Diabetes Infectious Disease HIV Tropical disease Liver Respiratory * HAIs Sexual Health Workplace 1, Government Toxicology Pain mgmt Hospitals 1, Reference Lab OEM & Retail * Company estimates.

6 Rapidly Growing Addressable Markets $17.1B $6.8B Forensics Immunochemistry $10.3B Molecular Diagnostics $8.4B Infectious disease Disease Infectious Disease Cardiometabolic Cardiometabolic Cardio metabolic Toxicology Toxicology Toxicology 2013 POC Addressable Market 2018 Existing Market Growth New Markets 2018 Total Market Opportunity Source: Frost and Sullivan, BBC, BCC Research, Espicom, Cowen, Kalorama, Company Estimates 5

7 Our Products and Services

8 Infectious Disease: Global Leader in Lateral Flow Testing >600M tests sold in 2014 >190M malaria tests sold in 2014 UAT Testing Advocated by Worldwide Clinical Guidelines 2 #1 Position >120 countries HIV #1 in Flu Market leading tests in HIV, Malaria, Dengue, Respiratory 1 # of countries that utilize Alere HIV tests >50% Market Share in POL BCC Research, Espicom, Cowen, Calorama, Company Estimates. 2 Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults, Lionel A. Mandell et al; Clinical Infectious Diseases 2007; 44:S27 72.

9 Alere HIV Portfolio: Spanning the Continuum of Care Prevention Monitoring / Management / Care Prevention and Diagnosis Alere Pima CD4 Analyzer SD HIV Combo Staging & Monitoring Alere q HIV 1/2 VL Data Point Connectivity Determine HIV 1/2 Ag/Ab Combo Alere q HIV EID Co-Morbidities Epocal Creatinine Alere Determine TB LAM Ag 8

10 Alere i: Disrupting the Market Alere i Influenza A & B CLIA Waived Features Traditional Lateral Flow Lab-based Molecular Alere i Molecular Accuracy Molecular level results allow for improved sensitivity and specificity Decentralization Results at the point of care allow for feedback and adjustments to care Rapid Results Physicians, labs and hospitals desire rapid tests to improve workflow 9

11 Cardiometabolic Care Continuum Acute Chronic Chronic at Home Markets: Emergency Departments In-Patient Testing Markets: Office-Based Testing Pharmacies Market: Home Testing Products: Products: Products: Triage epoc LDX Triage Alere Home Monitoring Afinion RALS INRatio Afinion Nycocard Arriva epoc Blood Analysis System Alere Afinion Analyzer Alere Home Monitoring 10

12 Acute Care Portfolio RALS Data Management System Leading Solutions. One Partner Alere i Alere Triage System epoc System 3 rd Party POCT 11

13 Chronic Care Management in Multiple Settings Alere Cholestech LDX Alere Afinion Analyzer Solutions for: Physician practices Retail settings Home Early intervention at the point of care, with ease of use and accessible cost 900+ MinuteClinics (CVS Health) have adopted LDX and Afinion systems Alere INRatio 2 NycoCard 12

14 Toxicology: Driving Growth Core Clinical Trade Segments: Employer Government Segments: Pain Lab Hospital Segments: OEM Reference Lab Strategies: Full Solutions Innovation (Global, Dx Testing) Strategies: Stabilize in Pain Regain Hospital share with new Triage Tox product Strategy: Launch 8-10 new reagents to enter untapped markets Integrated ereader Triage Clinical Panel Reagents 13

15 Comprehensive Toxicology Portfolio Toxicology Products Specialty Lab Services Program Management 25 reagents 32 rapid tests Small instruments 83 drugs Urine, saliva, hair Global Reach 4,000 collection sites 75% e-enabled Exclusive e-reader Reagents e-enabled Global Collection Network Rapids Electronic Drug Test Management Triage Clinical Panel Mobile Meters Lab Screening Complex Analysis Integrated ereader 14

16 Financial Overview 15

17 Historical Revenue $Millions $3, $2,394.4 $2,616.4 $2,588.7 $2, $1,946.2 $2, $1,686.7 $1, $1, $ $ Revenue excludes Alere Health entities sold to Optum in January 2015

18 2015 Organic Growth Key growth drivers Growth to accelerate as year progresses International sales (China, India, Africa, Latin America) epoc availability Afinion Alere i (Flu A/B, Strep A) HIV (Determine Combo, CD4, Alere q) Core Toxicology Toxicology Reagents

19 Aggressively Paying Down Debt $3.53B $3.35B $2.77B Q Q Q Post Divestitures Note: Figures represent net debt. 18

20 Divestiture Initiatives Entity Description BBI Clinical reagents Wampole/Techlab Clinical reagents Collectively, businesses contributed $184M revenue, $58.6M EBITDA in 2014 (1) SPD 50% JV with P&G, Women s Health (1) EBITDA amounts include equity income earned on 50% interest in SPD and 49% interest in Techlab. 19

21 2015 Revenue and EPS Guidance (As of May 29, 2015) Revenue $2.5B - $2.6B Adjusted Diluted EPS $ $2.50* * Adjusted diluted EPS excludes restructuring charges, amortization and other items of a similar nature to those excluded in prior periods. For a summary of adjustments to earnings in 2014, see

22 First Quarter 2015 Results ($ millions, except EPS) GAAP Non-GAAP Net Revenue $608.2 $608.4 Gross Margin % Total OpEx % R&D % SG&A % Income (Loss) Cont. Operations $(12.9) $45.1 * Please visit to view our Q1-15 Press Financials which contain detailed reconciliations of the non-gaap financial measures under GAAP. Diluted EPS $(0.15) $0.53 * Please visit: to view our Q1-15 Press Financials which contain detailed reconciliations of the non-gaap financial measures under GAAP.

23 Building on Our Momentum Growth Innovation Operating Leverage Grow at market (>5%) Focus resources on outpatient Enter MDx International markets Launch new products Double TAM to $17B by 2018 Rapidly populate existing platforms Enhance instruments Invest in MDx Quality culture Improve time to market OpEx discipline New products drive margin improvement Global procurement Manufacturing: - Low cost regions - Automation/Lean - Footprint reduction Restructure debt Tax planning

24 2015 Alere. All rights reserved. The Alere Logo, Alere, Afinion, Cholestech LDX, Determine, DDS, epoc, ereader, INRatio, Knowing now matters, MeterPro, Pima and Triage are trademarks of the Alere group of companies.